Le dabrafénib associé au tramétinib en deuxième ligne de traitement du cancer du poumon porteur de la mutation BRAF V600 permet d’obtenir une survie sans progression de 15 mois ! – Sina Finance
转自： 医学界网站BRAF突变患者， 二线接受“D+T”双靶治疗， 安全性良好， 长生存获益。
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Questions frequentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
